3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Lymphocytic, Chronic, B-Cell
3
Neoplasms
2
Hematologic Neoplasms
2
Rare Diseases
1
Neurologic Manifestations
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Myasthenia Gravis
1
Mental Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia
1
Infections
1
Burkitt Lymphoma
1
Agammaglobulinemia
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
9
Ciprofloxacin
7
Voriconazole
5
Caspofungin
4
Amoxicillin-Potassium Clavulanate Combination
4
gamma-Globulins
3
Vancomycin
3
Fluconazole
3
Filgrastim
3
Daptomycin
3
Antibiotic Prophylaxis
3
plerixafor
2
liposomal amphotericin B
2
Trimethoprim
2
Therapeutics
2
Sulfamethoxazole
2
Saline Solution
2
Ribavirin
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Pentetic Acid
2
Moxifloxacin
2
Melphalan
2
Levofloxacin
2
Itraconazole
2
Immunoglobulins, Intravenous
2
Granulocyte Colony-Stimulating Factor
2
Ethanol
2
Cyclophosphamide
2
Cefazolin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Infections
×
Immunoglobulins
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled